Serum Anti-Müllerian Hormone as a Predictor of Polycystic Ovarian Syndrome among Women of Reproductive Age
Background: The Polycystic Ovarian Syndrome (PCOS) affects up to a fifth of women of reproductive age and causes anovulatory subfertility. Some studies have recommended that an Anti-Müllerian Hormone (AMH) level greater than 3.8-5 ng/mL can be used for diagnosing PCOS. Therefore, this study aims to analyze the serum AMH level as a predictor of PCOS among women of reproductive age.Methods: A total of 51 women of reproductive age, recently diagnosed with PCOS (meeting the Rotterdam criteria),
... selected. A cross-sectional study design was used to estimate the AMH levels among PCOS women. Baseline variables, menstrual cycle length, ovarian morphology on the ultrasound, hirsutism, sex hormones, gonadotropin, and serum AMH levels were analyzed during the follicular phase (1–5 days) of the menstrual cycle. Results: A high serum AMH level (7.23 ± 4.67 ng/ml) was recorded with normal sex hormone levels. Women with oligo-/amenorrhea had a significant mean difference for luteinizing hormone (p=0.02) and AMH levels (p=0.03) when compared with women of normal menstrual cycle length. PCOS women with high AMH levels (≥3.9 ng/ml) showed a significant difference in ovarian morphology (p<0.05) when compared with the normal AMH group. Conclusions: Serum AMH level can be used as a strong predictor for disturbance in reproductive characteristics such as menstrual cycle disturbance, polycystic ovarian morphology, and clinical signs of hyperandrogenism. An elevated serum AMH level could reflect the certainty of PCOS diagnosis among women of reproductive age with a greater number of PCOS features.